OUR NEWS - FAST TRACK SERVICE
The Chaudière-Appalaches Integrated Health and Social Services Centre Authorized a First Clinical Trial in 8.4 Weeks With the FAST TRACK Evaluation Service and Recruited the First Canadian Participant
The Chaudière-Appalaches Integrated Health and Social Services Centre Authorized a First Clinical Trial in 8.4 Weeks With the FAST TRACK Evaluation Service and Recruited the First Canadian Participant The very first collaboration between the Chaudière-Appalaches Centre intégré de santé et de services sociaux (integrated health and social services centre or CISSS) and CATALIS’ FAST TRACK Evaluation Service has been
Bayer: The CHUM Was Ranked First in the World After Using the FAST TRACK Evaluation Service for the First Time
Bayer: The CHUM Was Ranked First in the World After Using the FAST TRACK Evaluation Service for the First Time The Bayer pharmaceutical company used the FAST TRACK Evaluation Service for the first time to accelerate the authorization of its PAnTHA advanced prostate cancer trial at the Centre hospitalier de l’Université de Montréal (CHUM) in 10.4 weeks, with site
A New Brand Identity for the FAST TRACK Evaluation Service
Almost 2 years after its inauguration, the FAST TRACK Evaluation Service is unveiling a new brand identity. Officially launched by the CATALIS Network in September 2022, the FAST TRACK Evaluation Service aims to authorize clinical trials in ≤ 8 weeks. We are pleased to announce that, to date, the service has enabled the authorization of 37 clinical trials conducted by
BeiGene: A First Trial Authorized With a Median Time of 8.1 Weeks
BeiGene: A First Trial Authorized With a Median Time of 8.1 Weeks Thanks to CATALIS’ FAST TRACK Evaluation Service, the BeiGene pharmaceutical company accelerated the authorization for its trial on chronic lymphoid leukemia (BGB-11417-301) in 3 Quebec hospitals with a median time of 8.1 weeks. In fact, the CHU-Sherbrooke authorized the trial in 7.8 weeks and became the first site
GSK Authorized 3 First Trials With a Median Time of 8.4 Weeks and Activated the First Site Globally
GSK Authorized 3 First Trials With a Median Time of 8.4 Weeks and Activated the First Site Globally Thanks to CATALIS’ FAST TRACK Evaluation Service and its participating healthcare institutions, the GlaxoSmithKline Inc. (GSK) pharmaceutical company was able to accelerate the authorization of three clinical trials, with a record median time of 8.4 weeks. The Galaxies 202 trial, which
First Pfizer Pharmaceutical Company Trial Authorized With a Median of 8.2 Weeks Using the FAST TRACK Evaluation Service
First Pfizer Pharmaceutical Company Trial Authorized With a Median of 8.2 Weeks Using the FAST TRACK Evaluation Service For the first time, the Pfizer pharmaceutical company used CATALIS’ FAST TRACK Evaluation Service to authorize a complex Phase Ia/Ib oncology clinical trial, meaning a master protocol that includes several sub-studies. In this study, Pfizer is assessing the effectiveness of a
Catalis in Support of the Quebec Government’s Policy on Rare Diseases
CATALIS in Support of the Quebec Government’s Policy on Rare Diseases On June 6, the Quebec government unveiled its Politique québécoise pour les maladies rares (Quebec policy on rare diseases – in French only). In Quebec, 700,000 people with rare diseases, half of whom are children, face significant challenges such as errors in diagnosing their disease and the absence
MASter-1 Study: Authorization in 8 Weeks to Explore a New Treatment for an Extremely Rare Disease
MASter-1 Study: Authorization in 8 Weeks to Explore a New Treatment for an Extremely Rare Disease As mentioned in our December 2022 newsletter, CATALIS is proud to support the Quebec government’s Politique québécoise sur les maladies rares (Quebec policy on rare diseases – in French only), namely by allowing studies to be activated more quickly thanks to its FAST
STRENGTH Study: Zolgensma for Children Aged 2 to 12 With Spinal Muscular Atrophy
STRENGTH Study: Zolgensma for Children Aged 2 to 12 With Spinal Muscular Atrophy In October 2021, Minister Dubé announced that Zolgensma, a drug produced by the Novartis pharmaceutical company, was added to the list of drugs offered in Quebec health facilities to treat children under the age of 2 with spinal muscular atrophy. Spinal muscular atrophy is a rare
NEPTUNUS-2 Study: Sjogren’s Syndrome Clinical Trial Approved in 8 Weeks via CATALIS’ FAST TRACK Evaluation Service
NEPTUNUS-2 Study: Sjogren’s Syndrome Clinical Trial Approved in 8 Weeks via CATALIS’ FAST TRACK Evaluation Service As mentioned in our December 2022 newsletter, CATALIS is proud to announce that its FAST TRACK Evaluation Service continues to allow industry-financed studies to be authorized in record time. In NEPTUNUS-2, a phase III study, Novartis and Dr. Isabelle Fortin are testing the
ONWARDS Study: Authorization in 9 Weeks for Symptomatic Osteoarthritis of the Knee Study via CATALIS’ FAST TRACK Evaluation Service
ONWARDS Study: Authorization in 9 Weeks for Symptomatic Osteoarthritis of the Knee Study via CATALIS’ FAST TRACK Evaluation Service In addition to the 3 rare disease studies, a 4th Novartis study on symptomatic osteoarthritis of the knee was authorized by the Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS) in record time via the CATALIS FAST TRACK
Sanofi Pharmaceutical Company’s First Clinical Trial Approved Through CATALIS Quebec’s FAST TRACK Evaluation Service
Sanofi Pharmaceutical Company’s First Clinical Trial Approved Through CATALIS Quebec’s FAST TRACK Evaluation Service Following Novartis, Boehringer, and Roche, Sanofi is now CATALIS’ fourth pharmaceutical partner to pilot its FAST TRACK Evaluation Service. Sanofi’s Phase I-ll study, which uses human subjects for the first time and is designed to assess the safety and the pharmacokinetic, pharmacodynamic, and antitumor activity
Roche Pharmaceutical Company’s First Clinical Trial Approved Through CATALIS Quebec’s FAST TRACK Evaluation Service
Roche Pharmaceutical Company’s First Clinical Trial Approved Through CATALIS Quebec’s FAST TRACK Evaluation Service Thanks to CATALIS’ FAST TRACK evaluation service, Roche’s ProHer multi-centre study, which explores a new treatment method for patients with breast cancer, was approved in 10 weeks by the CHU de Québec-Université Laval. More specifically, this study seeks to discover patients’ preference for at-home administration
Two New Projects Successfully Authorized Within Seven Weeks Thanks to CATALIS QUEBEC’S FAST TRACK Evaluation Service
Two New Projects Successfully Authorized Within Seven Weeks Thanks to CATALIS QUEBEC’S FAST TRACK Evaluation Service While the first-ever FAST TRACK evaluation service pilot project was successfully completed last December, CATALIS is proud to announce that two more clinical trials have now been approved in record time. The second FAST TRACK evaluation service coordinated a Phase I oncology study
A First Successful Pilot Project for CATALIS’ New FAST TRACK Evaluation Service: 4 Quebec Institutions Ranked in the Top 5 of the World’s Fastest Sites
A First Successful Pilot Project for CATALIS’ New FAST TRACK Evaluation Service: 4 Quebec Institutions Ranked in the Top 5 of the World’s Fastest Sites CATALIS is very proud to announce that the first pilot of its new FAST TRACK assessment service has successfully reduced the approval time for an industry-financed clinical trial by almost 75%. In September 2021,
CATALIS Is Piloting Its New FAST TRACK Evaluation Service
The CATALIS Public-Private Network has developed a new FAST TRACK evaluation service that will eventually allow industry-funded clinical trials to be authorized in less than 8 weeks.